The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Open accessPublished version of a preprint
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired a D614G mutation early in the pandemic that confers greater infectivity and is now the globally dominant form. To determine whether D614G might also mediate neutralization escape that could compromise vaccine efficacy, sera from spike-immunized mice, nonhuman primates, and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 spike. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by receptor-binding domain (RBD) monoclonal antibodies and convalescent sera from people infected with either form of the virus. Negative stain electron microscopy revealed a higher percentage of the 1-RBD "up" conformation in the G614 spike, suggesting increased epitope exposure as a mechanism of enhanced vulnerability to neutralization. Based on these findings, the D614G mutation is not expected to be an obstacle for current vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to previous studies from our group (15) and others (18), pseudovirus neutralization titers to D614G were threefold higher than to WA1 (Fig. 2G).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKorber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 4×
“This is the immunogen being employed in the Moderna vaccine in phase 3 clinical trials (mRNA1273, NCT04470427) (Jackson et al., 2020).”
InfluentialCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Self-citationCross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–332 of 332
Homology Modeling and Evaluation of Sars-Cov-2 Spike Protein Mutant
Vyshnavi, A. M. H., Mohan, A., Naisam, S., Kumar, S., & Sreekumar, N. (2021) · International Journal of Quantitative Structure-Property Relationships · doi:10.4018/ijqspr.2021100103
Yuan, L., Zhu, H., Zhou, M., Ma, J., Chen, P., Liu, X., Wu, K., Chen, R., Liu, Q., Hou, W., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3903926
Rice, A., Verma, M., Voigt, E. A., Battisti, P., Beaver, S., Reed, S., Dinkins, K., Mody, S., Zakin, L., Tanaka, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.29.470440
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.09.471953
Are the emerging SARS-COV-2 mutations friend or foe?Preprint
Erol, A. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/zgmk4
Ergenç, Z., Ergenç, H., Öztürk, A., Kaya, G., Ocak, Ö. K., & İnce, Ö. (2022) · Journal of Acute Disease · doi:10.4103/2221-6189.362815
Fuentes-Acosta, M., Mulia-Rodríguez, J., & Osorio-González, D. (2023) · Creative Education · doi:10.4236/ce.2023.141008
SARS-CoV-2: Structure, Pathogenesis, and Diagnosis
Goverdhan, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00002-6
Nandi, J. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13267-4.00005-3
Immunological storm and multiple organ damage by COVID-19
Arafath, A. Y., Fathima, S. A., Prabhakaran, A., Hassan, S., Prathiviraj, R., Kiran, G. S., & Selvin, J. (2024) · Medicine in Omics · doi:10.1016/j.meomic.2024.100034
Molecular recognition of anion binding proteins: Characterization and inhibition
Schuurs, Z. P. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.246091
Homology Modeling and Evaluation of Sars-Cov-2 Spike Protein Mutant
Vyshnavi, A. M. H., Mohan, A., Naisam, S., Kumar, S., & Sreekumar, N. (2023) · IGI Global eBooks · doi:10.4018/979-8-3693-3026-5.ch039
Disappearance of Imported Cases of Omicron Lineage BA.2.40 in West Kalimantan, Indonesia.
Liana, D. F., Novianry, V., Andriani, A., Mahyarudin, M., & Astuti, P. (2024) · PubMed Central · doi:10.30476/ijms.2023.97513.2935
Current Progress in Genomic and Genetic Research on Human Viral Diseases
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4833-2 · Cited by 1
Yang, Y., Lin, Y.-J., You, S., Lu, T., Chen, C., Wang, W.-M., Ling, M., Chen, S., & Liao, C. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s480086
Uzgan, T., Schulte, B., & Yalçın, H. T. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11359-5
Additional file 3 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555534
Additional file 7 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555546
Additional file 10 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555555
Additional file 9 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555552
Additional file 6 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555543
Additional file 4 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555537
Additional file 8 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555549
Additional file 1 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555528
Additional file 2 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555531
Additional file 5 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555540
Xu, Y., Fang, W., Wang, S., Luo, H.-B., Xu, Q., Chen, F.-E., Qu, J., & Sun, Y. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100158
Depierreux, D. M., Ruiz, F., Lilly, M., Guenthoer, J., Chohan, V., & Overbaugh, J. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014026
Samuels, R. J., Bond, N. G., Sumah, I., Grant, D. S., Kamara, M. S., BAZZANO, L., Fernandez, C., Borrega, R., Chandra, S., Glezer, C., et al. (2026) · Immunity Inflammation and Disease · doi:10.1002/iid3.70463
Ugurlu, Ö., Prather, A. A., Epel, E. S., & Guevarra, D. A. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101286
Characterization of SARS-CoV-2 Spike mutations
Schotsaert, M. (2025) · ImmPort · doi:10.21430/m301eut53a
Metadata
- Authors
- Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., Mansouri, K., Gobeil, S., McDanal, C., Pardi, N., Hengartner, N., Lin, P. J. C., Tam, Y., Shaw, P. A., Lewis, M. G., Boesler, C., Şahin, U., Acharya, P., Haynes, B. F., Korber, B., & Montefiori, D. C.
- Affiliations
- University of Pennsylvania (US)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- University of Sheffield (GB)
- Duke University (US)
- Beth Israel Deaconess Medical Center (US)
- Acuitas Therapeutics (Canada) (CA)
- Bioqual (US)
- BioNTech (Germany) (DE)
- Los Alamos National Laboratory (US)
- Corresponding author
- Weissman, Drew
- ORCID
- Weissman, Drew
- Alameh, Mohamad-Gabriel
- Collini, Paul
- Hornsby, Hailey
- Brown, Rebecca
- LaBranche, Celia C.
- Edwards, Robert J.
- Sutherland, Laura
- Santra, Sampa
- Mansouri, Katayoun
- Gobeil, Sophie
- McDanal, Charlene
- Pardi, Norbert
- Lin, Paulo J.C.
- Tam, Ying
- Shaw, Pamela A.
- Lewis, Mark G.
- Boesler, Carsten
- Şahin, Uğur
- Acharya, Priyamvada
- Haynes, Barton F.
- Korber, Bette
- Montefiori, David C.
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 29
- Issue
- 1
- Pages
- 23-31.e4
- ISSN
- 1931-3128 (ISSN-L)
- PMC
- PMC7707640
- OpenAlex
- W3108737416
- Cited by
- 324
- References
- 57
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 17 · 2023: 33 · 2022: 72 · 2021: 173
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell Host & Microbe (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- National Institutes of Health (75N93019C00050, HHSN272201800004C, R01 - AI145687)
- Wellcome Trust (110058/Z/15/Z)
- National Institute of Allergy and Infectious Diseases (AI142596, AI124429, R01AI123738, 1R01AI146101)
- University of Pennsylvania
- National Institute for Health Research
- Laboratory Directed Research and Development (20200706ER)
- Bill and Melinda Gates Foundation (OPP1146996)
- UK Research and Innovation
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, spike protein, D614G mutation, neutralizing antibodies, neutralization escape, receptor binding domain, monoclonal antibodies, convalescent sera, epitope exposure, vaccine efficacy, pseudovirus
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Serotherapy, Adolescent, Adult, Animals, Antibodies, Monoclonal, Binding Sites, Female, Humans, Immunization, Passive, Macaca mulatta, Male, Mice, Inbred BALB C, Middle Aged, Mutation, Neutralization Tests, Mice, Young Adult, HEK293 Cells, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
